- Home
- ATAI vs AQST Comparison
ATAI vs AQST Comparison
Compare ATAI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- AQST
- Stock Information
- Founded
- ATAI 2018
- AQST 2004
- Country
- ATAI Germany
- AQST United States
- Employees
- ATAI N/A
- AQST N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- AQST Health Care
- Exchange
- ATAI Nasdaq
- AQST Nasdaq
- Market Cap
- ATAI 280.2M
- AQST 274.4M
- IPO Year
- ATAI 2021
- AQST 2018
- Fundamental
- Price
- ATAI $1.48
- AQST $2.84
- Analyst Decision
- ATAI Strong Buy
- AQST Strong Buy
- Analyst Count
- ATAI 4
- AQST 7
- Target Price
- ATAI $9.00
- AQST $10.57
- AVG Volume (30 Days)
- ATAI 2.8M
- AQST 1.5M
- Earning Date
- ATAI 03-27-2025
- AQST 03-05-2025
- Dividend Yield
- ATAI N/A
- AQST N/A
- EPS Growth
- ATAI N/A
- AQST N/A
- EPS
- ATAI N/A
- AQST N/A
- Revenue
- ATAI $331,000.00
- AQST $57,561,000.00
- Revenue This Year
- ATAI $80.07
- AQST N/A
- Revenue Next Year
- ATAI N/A
- AQST $35.72
- P/E Ratio
- ATAI N/A
- AQST N/A
- Revenue Growth
- ATAI N/A
- AQST 13.80
- 52 Week Low
- ATAI $1.03
- AQST $2.24
- 52 Week High
- ATAI $2.85
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- ATAI 41.75
- AQST 48.60
- Support Level
- ATAI $1.37
- AQST $2.45
- Resistance Level
- ATAI $1.50
- AQST $3.06
- Average True Range (ATR)
- ATAI 0.14
- AQST 0.22
- MACD
- ATAI -0.04
- AQST 0.02
- Stochastic Oscillator
- ATAI 29.73
- AQST 63.93
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.